2seventy bio completes $40m haemophilia A program deal with Novo Nordisk [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
2seventy bio will potentially receive up to $40m under the deal, which brings an end to a research agreement established between the companies in 2019. The deal focused on developing a gene editing therapy for people with haemophilia A. Haemophilia is a rare disorder in which blood does not clot in a typical way because it doesn't have enough blood-clotting proteins. Novo Nordisk will also receive rights to 2seventy's MegaTAL in vivo gene editing technology for its applications in projects other than those involving oncology and autoimmune disorders. 2seventy bio team members currently involved in the program will join Novo Nordisk to continue advancing the technology. “Novo Nordisk has been a valued partner over the past five years, and we are confident that under their leadership, the promise of developing a new treatment approach for patients living with hemophilia A will continue to progress,” commented 2seventy bio CEO Chip Baird. 2seventy bio has said it will now focu
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Fixing the Broken Rung: Better approaches to promotion and talent development [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN [Yahoo! Finance]Yahoo! Finance
- Keep faith in China, Li Qiang tells business at ‘Summer Davos' [Yahoo! Finance]Yahoo! Finance
- SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women [Yahoo! Finance]Yahoo! Finance
- Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 6/26/24 - Form 6-K
- 6/24/24 - Form 6-K
- 6/21/24 - Form 11-K
- NVO's page on the SEC website